Akthelia Pharmaceuticals
Akthelia Pharmaceuticals is a pioneering biopharmaceutical company focused on developing therapeutics that enhance the body's innate defense mechanisms to combat debilitating diseases. The company targets mucosal barrier injury and epithelial integrity through a novel immunotherapeutic strategy. Its mission is to revolutionize treatment for diseases such as cancer, infection, and autoimmune disorders by leveraging the body's own microbial defense mechanisms.
Akthelia Pharmaceuticals
Grandagardi 16, 101 Reykjavik, Iceland
What We Do
Akthelia focuses on developing small molecule therapeutics that enhance epithelial surfaces to counteract disease pathogenesis, with applications in oncology, gastroenterology, and other medical fields.
A late preclinical stage oral therapeutic aimed at reducing chemotherapy-induced bloodstream infections by enhancing the gastrointestinal epithelium's immune response.
Drugs
Key People
News & Updates
The article highlights Akthelia's promising oral NCE therapeutic asset Gastrimod™️ (AKT-011) for oncology and inflammatory bowel disorders.
Akthelia received a $350,000 grant from RANNIS to support the development of Gastrimod® (AKT-011) for chemotherapy-induced febrile neutropenia.
Akthelia presented new data on mucosal barrier injury at the Nordic Life Science Days 2024, highlighting their strategic roadmap and partnerships.
Akthelia received the European Commission Seal of Excellence, recognizing its innovative approach in biopharmaceutical development.